WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001030331) THERAPEUTIC COMPOSITIONS INCLUDING PROTEIN KINASE C INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/030331    International Application No.:    PCT/US2000/026254
Publication Date: 03.05.2001 International Filing Date: 13.10.2000
Chapter 2 Demand Filed:    30.04.2001    
IPC:
A61K 45/06 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US) (For All Designated States Except US).
CAMERON, Norman, Eugene [GB/GB]; (GB) (For US Only).
WAYS, Douglas, Kirk [US/US]; (US) (For US Only)
Inventors: CAMERON, Norman, Eugene; (GB).
WAYS, Douglas, Kirk; (US)
Agent: DARKES, Paul, J.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US)
Priority Data:
60/161,129 22.10.1999 US
60/177,510 21.01.2000 US
Title (EN) THERAPEUTIC COMPOSITIONS INCLUDING PROTEIN KINASE C INHIBITORS
(FR) COMPOSITIONS THERAPEUTIQUES COMPRENANT DES INHIBITEURS DE LA PROTEINE KINASE C
Abstract: front page image
(EN)Compositions comprising a PKC inhibitor, or a pharmaceutically acceptable salt thereof, and an antioxidant, essential fatty acid, or a prostacyclin agent, or a pharmaceutically acceptable salt thereof are provided. Also provided are methods of treatment comprising administration of such compositions, and methods of treatment comprising co-administration of a PKC inhibitor, or a pharmaceutically acceptable salt thereof, and an antioxidant, essential fatty acid, or a prostacyclin agent, or a pharmaceutically acceptable salt thereof.
(FR)L'invention concerne des compositions comprenant un inhibiteur de la protéine kinase C (PKC), ou un sel de celui-ci acceptable d'un point de vue pharmaceutique, et un acide gras essentiel antioxydant, ou un agent de prostacycline, ou un sel de celui-ci acceptable d'un point de vue pharmaceutique. L'invention concerne également des méthodes de traitement consistant à administrer ces compositions, et des méthodes de traitement consistant à co-administrer un inhibiteur de la PKC, ou un sel de celui-ci acceptable d'un point de vue pharmaceutique, et un acide gras essentiel antioxydant, ou un agent de prostacycline, ou un sel de celui-ci acceptable d'un point de vue pharmaceutique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)